Literature DB >> 36242734

Anti-apoptotic Splicing Variant of AIMP2 Recover Mutant SOD1-Induced Neuronal Cell Death.

Myung Geun Kook1,2, Mi Ran Byun3,4, Soo Min Lee3,5, Min Hak Lee3,5, Dae Hoon Lee3,5, Hyung Been Lee5, Eui-Jin Lee3,5, Kyunghwa Baek4,6, Sunghoon Kim7, Kyung-Sun Kang8,9, Jin Woo Choi10,11.   

Abstract

Although a couple of studies have reported that mutant superoxide dismutase 1 (SOD1), one of the causative genes of familial amyotrophic lateral, interacts physically with lysyl-tRNA synthetase (KARS1) by a gain of function, there is limited evidence regarding the detailed mechanism about how the interaction leads to neuronal cell death. Our results indicated that the aminoacyl-tRNA synthetase-interacting multi-functional protein 2 (AIMP2) mediated cell death upon the interplay between mutant SOD1 and KARS1 in ALS. Binding of mutant SOD1 with KARS1 led to the release of AIMP2 from its original binding partner KARS1, and the free form of AIMP2 induced TRAF2 degradation followed by TNF-α-induced cell death. We also suggest a therapeutic application that overexpression of DX2, the exon 2-deleted antagonistic splicing variant of AIMP2 (AIMP2-DX2), reduced neuronal cell death in the ALS mouse model. Expression of DX2 suppressed TRAF2 degradation and TNF-α-induced cell death by competing mode of action against full-length AIMP2. Motor neuron differentiated form iPSC showed a resistance in neuronal cell death after DX2 administration. Further, intrathecal administration of DX2-coding adeno-associated virus (AAV) improved locomotive activity and survival in a mutant SOD1-induced ALS mouse model. Taken together, these results indicated that DX2 could prolong life span and delay the ALS symptoms through compensation in neuronal inflammation.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  AIMP2; Amyotrophic lateral sclerosis; DX2; KARS1; SOD1; TRAF2

Year:  2022        PMID: 36242734     DOI: 10.1007/s12035-022-03073-1

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.682


  61 in total

Review 1.  The dual roles of immunity in ALS: injury overrides protection.

Authors:  Benjamin J Murdock; Diane E Bender; Benjamin M Segal; Eva L Feldman
Journal:  Neurobiol Dis       Date:  2015-02-26       Impact factor: 5.996

Review 2.  Therapeutic development in amyotrophic lateral sclerosis.

Authors:  Monica Bucchia; Agnese Ramirez; Valeria Parente; Chiara Simone; Monica Nizzardo; Francesca Magri; Sara Dametti; Stefania Corti
Journal:  Clin Ther       Date:  2015-02-07       Impact factor: 3.393

Review 3.  The epidemiology of ALS: a conspiracy of genes, environment and time.

Authors:  Ammar Al-Chalabi; Orla Hardiman
Journal:  Nat Rev Neurol       Date:  2013-10-15       Impact factor: 42.937

Review 4.  Amyotrophic lateral sclerosis.

Authors:  Michael A van Es; Orla Hardiman; Adriano Chio; Ammar Al-Chalabi; R Jeroen Pasterkamp; Jan H Veldink; Leonard H van den Berg
Journal:  Lancet       Date:  2017-05-25       Impact factor: 79.321

Review 5.  Concise review: Stem cell therapies for amyotrophic lateral sclerosis: recent advances and prospects for the future.

Authors:  J Simon Lunn; Stacey A Sakowski; Eva L Feldman
Journal:  Stem Cells       Date:  2014-05       Impact factor: 6.277

Review 6.  Drugs in clinical development for the treatment of amyotrophic lateral sclerosis.

Authors:  Ana Martinez; Maria Del Valle Palomo Ruiz; Daniel I Perez; Carmen Gil
Journal:  Expert Opin Investig Drugs       Date:  2017-03-14       Impact factor: 6.206

7.  SOD1 mRNA expression in sporadic amyotrophic lateral sclerosis.

Authors:  Stella Gagliardi; Emanuela Cova; Annalisa Davin; Stefania Guareschi; Kenneth Abel; Elena Alvisi; Umberto Laforenza; Roberta Ghidoni; John Richard Cashman; Mauro Ceroni; Cristina Cereda
Journal:  Neurobiol Dis       Date:  2010-04-23       Impact factor: 5.996

Review 8.  Molecular biology of amyotrophic lateral sclerosis: insights from genetics.

Authors:  Piera Pasinelli; Robert H Brown
Journal:  Nat Rev Neurosci       Date:  2006-09       Impact factor: 34.870

9.  Edaravone: A new drug approved for ALS.

Authors:  Jeffrey D Rothstein
Journal:  Cell       Date:  2017-11-02       Impact factor: 41.582

Review 10.  Genetic testing and genetic counseling for amyotrophic lateral sclerosis: an update for clinicians.

Authors:  Jennifer Roggenbuck; Adam Quick; Stephen J Kolb
Journal:  Genet Med       Date:  2016-08-18       Impact factor: 8.822

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.